Abstract
Cancer uses local factors to activate the ever-present osteoclasts in bone to prepare a cavity into which it may grow. For this reason, medical treatments have targeted the recruitment of osteoclasts to decrease metastasis. At the moment two major classes of drugs are utilized for this purpose: the bisphosphonates and the more-recent arrival denosumab. This chapter summarizes the mechanisms of action and modes of use in metastatic bone treatment of these drugs, along with their side effects and how these may be addressed.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19.
Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49(1):42–9.
Ebetino FH, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49(1):20–33.
Russell RG, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209–57.
McClung MR, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–31.
Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006;39(3):443–52.
Hanley DA, et al. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139–46.
Machado M, et al. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther. 2009;31(5):962–79.
Young RJ, Coleman RE. Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol. 2013;9(5):633–43.
Mhaskar R, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188.
Mahindra A, Pozzi S, Raje N. Clinical trials of bisphosphonates in multiple myeloma. Clin Adv Hematol Oncol. 2012;10(9):582–7.
Palmieri C, Fullarton JR, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res. 2013;19(24):6863–72.
Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558–67.
Ringe JD, Body JJ. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol. 2007;25(5):766–74.
Ross JR, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ. 2003;327(7413):469.
Brown JP, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29(9):2051–6.
Keaveny TM, et al. Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. J Bone Miner Res. 2014;29(1):158–65.
Genant HK, et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone. 2010;47(1):131–9.
Reagan P, Pani A, Rosner MH. Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis. 2014;63(1):141–7.
Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.
Henry DH, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125–32.
Henry D, et al. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22(3):679–87.
Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone. 2007;40(4):1144–51.
Paget S. Steroids cause osteoporosis. Ann Rheum Dis. 2002;61(1):1–3.
Perrot S, Le Jeunne C. Steroid-induced osteoporosis. Presse Med. 2012;41(4):406–13.
Manolagas SC. Steroids and osteoporosis: the quest for mechanisms. J Clin Invest. 2013;123(5):1919–21.
Bamias A, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–7.
Bi Y, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol. 2010;177(1):280–90.
Qi WX, et al. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19(2):403–10.
Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res. 2014;29(1):1–23.
Puhaindran ME, et al. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates. J Bone Joint Surg Am. 2011;93(13):1235–42.
Chang ST, et al. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone. 2012;51(3):524–7.
Drampalos E, et al. Atypical femoral fractures bilaterally in a patient receiving denosumab. Acta Orthop. 2014;85(1):3–5.
Schilcher J, Aspenberg P. Atypical fracture of the femur in a patient using denosumab—a case report. Acta Orthop. 2014;85(1):6–7.
Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. Bone. 2014;61:44–7.
Bobyn JD, et al. Locally delivered bisphosphonate for enhancement of bone formation and implant fixation. J Bone Joint Surg Am. 2009;91 Suppl 6:23–31.
Tanzer M, et al. The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution. Clin Orthop Relat Res. 2005;441:30–9.
Bobyn JD, et al. Local alendronic acid elution increases net periimplant bone formation: a micro-CT analysis. Clin Orthop Relat Res. 2014;472(2):687–94.
Healey JH, et al. PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res. 2003;(Suppl 415):S263–75.
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–93.
Bruning PF, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer. 1990;61(2):308–10.
Healey JH. Metabolic bone disease: editorial overview – the epidemic of chemotherapy-related osteoporosis. Curr Opin Orthop. 1999;10(5):331–3.
Milgrom C, et al. The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. Bone. 2004;35(2):418–24.
Savaridas T, et al. Do bisphosphonates inhibit direct fracture healing? A laboratory investigation using an animal model. Bone Joint J. 2013;95-B(9):1263–8.
Rebolledo BJ, Unnanuntana A, Lane JM. A comprehensive approach to fragility fractures. J Orthop Trauma. 2011;25(9):566–73.
McClung M, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20.
Kong SY, et al. Effects of a “drug holiday” on bone mineral density and bone turnover marker during bisphosphonate therapy. J Bone Metab. 2013;20(1):31–5.
Brown JP, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324–33.
Black DM, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.
Nishida S, et al. Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone. 1994;15(6):717–23.
Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone. 2007;40(6):1447–52.
Aspenberg P, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25(2):404–14.
Ohtori S, et al. Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine (Phila Pa 1976). 2012;37(23):E1464–8.
Ohtori S, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine (Phila Pa 1976). 2013;38(8):E487–92.
Peichl P, et al. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93(17):1583–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Olgun, Z.D., Gianakos, A., Jo, J.E., Lane, J.M. (2016). Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease. In: Randall, R. (eds) Metastatic Bone Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5662-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-4614-5662-9_12
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-5661-2
Online ISBN: 978-1-4614-5662-9
eBook Packages: MedicineMedicine (R0)